Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus ENOVID E.
CYCLESSA vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive